Cargando…

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients with mHSPC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueda, Takashi, Shiraishi, Takumi, Ito, Saya, Ohashi, Munehiro, Matsugasumi, Toru, Yamada, Yasuhiro, Fujihara, Atsuko, Hongo, Fumiya, Okihara, Koji, Ukimura, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115638/ https://www.ncbi.nlm.nih.gov/pubmed/33980956 http://dx.doi.org/10.1038/s41598-021-89609-2

Ejemplares similares

Novel device for dividing core needle biopsy specimens to provide paired mirror image-like tissues for genetic and pathological tests
por: Nakamura, Yuichi, et al.
Publicado: (2023)

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
por: Narukawa, Tsukasa, et al.
Publicado: (2020)

Remitting seronegative symmetrical synovitis with pitting edema syndrome in maintenance hemodialysis
por: Matsugasumi, Toru, et al.
Publicado: (2020)

CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells
por: Ito, Saya, et al.
Publicado: (2018)

Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion
por: Shiraishi, Takumi, et al.
Publicado: (2020)

A big data-based prediction model for prostate cancer incidence in Japanese men
por: Kato, Mineyuki, et al.
Publicado: (2023)

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study
por: Inoue, Yuta, et al.
Publicado: (2023)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Bone marrow metastasis in a patient with non‐seminomatous testicular germ cell tumor
por: Ueda, Takashi, et al.
Publicado: (2022)

Gene expression profiles during tissue remodeling following bladder outlet obstruction
por: Ito, Saya, et al.
Publicado: (2021)

Double renal cell carcinoma with histological type of clear cell carcinoma and papillary carcinoma in the same kidney concurrently treated with robot‐assisted partial nephrectomy
por: Shimizu, Teruki, et al.
Publicado: (2021)

Importance of Continuous Sequential Chemotherapy and Multimodal Treatment for Advanced Testicular Cancer: A High-Volume Japanese Center Experience
por: Nakamura, Terukazu, et al.
Publicado: (2015)

Androgen suppresses testicular cancer cell growth in vitro and in vivo
por: Nakagawa, Hideo, et al.
Publicado: (2016)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Phase I study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol
por: Yamada, Yasuhiro, et al.
Publicado: (2019)

Prostate squamous cell carcinoma developing 11 years after external radiotherapy for prostate adenocarcinoma
por: Matsugasumi, Toru, et al.
Publicado: (2020)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Robot‐assisted laparoscopic partial nephrectomy for horseshoe kidney: A case report
por: Fujihara, Atsuko, et al.
Publicado: (2019)

Usefulness of bicarbonate Ringer's solution as perfusate during transurethral resection of the prostate
por: Hongo, Fumiya, et al.
Publicado: (2021)

Abiraterone Acetate
Publicado: (2012)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
por: Rzewuska, Anna Maria, et al.
Publicado: (2023)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
por: Purshouse, Karin, et al.
Publicado: (2019)

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
por: Tsaur, Igor, et al.
Publicado: (2021)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Evaluation of pregnancy outcomes using medroxyprogesterone acetate versus gonadotropin-releasing hormone antagonist in ovarian stimulation: A retrospective cohort study
por: Singh, Ekika, et al.
Publicado: (2022)

Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles
por: Tandulwadkar, Sunita, et al.
Publicado: (2023)

Original delayed-start ovarian stimulation protocol with a gonadotropin-releasing hormone antagonist, medroxyprogesterone acetate, and high-dose gonadotropin for poor responders and patients with poor-quality embryos
por: Takeuchi, Kazuhiro, et al.
Publicado: (2023)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Efficacy and Safety of gonadotropin-releasing hormone (GnRH) Agonists Triptorelin Acetate and Cetrorelix Acetate in Assisted Reproduction
por: Jiang, Jingjing, et al.
Publicado: (2018)

Invertebrate Gonadotropin-Releasing Hormone-Related Peptides and Their Receptors: An Update
por: Sakai, Tsubasa, et al.
Publicado: (2017)

Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist
por: Trudeau, Vance L, et al.
Publicado: (2010)

Luteinizing hormone changes in gonadotropin-releasing hormone antagonist protocol in in vitro fertilization cycles: A cross-sectional study
por: Hosein Rashidi, Batool, et al.
Publicado: (2019)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly
por: Yamazaki, Hideya, et al.
Publicado: (2020)

High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lovepb4aeuqje8j4smn3q01s20